NCT00337766

Desmopressin in Cardiac Surgery

Efficacy of Desmopressin (1-deamin0-8-D-arginine-vasopressin) in Reducing Active Microvascular Bleeding After Cardiac Surgery

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: —
• Sponsor: Università Vita-Salute San Raffaele · Academic / Other
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

Patients undergoing cardiac surgery could develop excessive perioperative bleeding requiring transfusions of blood products. Desmopressin (DDAVP), already used for patients with von Willebrand syndrome, could reduce bleeding and transfusion requirements in these patients when administered ev (0.3 mg/kg) in 20-30 minutes postoperatively.

Conditions

• Hemorrhage
• Blood Loss, Surgical
• Postoperative Hemorrhage

Interventions

Type	Name	Description
DRUG	Desmopressin (DDAVP)
DRUG	Placebo

Timeline

• Start date: 2006-06-01
• Primary completion: 2009-09-01
• Completion: 2010-09-01
• First posted: 2006-06-16
• Last updated: 2015-10-21

Locations

4 sites across 1 country: Italy